

Translational Research in Autoimmune Diseases

Lea Schmidt¹, Elena Klein², Oscar Moreau³

¹ Research Scientist, Institute of Intelligent Systems, Advanced Computing University, Paris, France. Email: lea.schmidt466@yahoo.com | ORCID: 2818-0223-4409-7332

² Professor, Department of Machine Learning, Mediterranean Institute of Technology, Rome, Italy. Email: elena.klein736@yahoo.com | ORCID: 4323-2827-6330-3765

³ Senior Lecturer, School of Data Science, Western Europe Data Science University, Madrid, Spain. Email: oscar.moreau799@yahoo.com | ORCID: 6826-7458-9547-7119

ABSTRACT

Autoimmune diseases affect approximately 5-8% of the global population, encompassing over 80 distinct conditions ranging from organ-specific disorders like type 1 diabetes and Hashimoto's thyroiditis to systemic conditions like lupus, rheumatoid arthritis, and multiple sclerosis. Despite significant advances in understanding the immunological basis of autoimmunity, translating bench discoveries into effective therapies remains frustratingly slow -- the average time from target identification to approved drug in autoimmunity exceeds 15 years, and the clinical trial failure rate surpasses 90%. We analysed the translational pipeline for autoimmune diseases by evaluating 2,864 translational research projects tracked across five European autoimmune research networks (Paris, Rome, Madrid, Berlin, and London) from 2010 to 2021, spanning rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS), inflammatory bowel disease (IBD), and psoriasis. We compared five translational frameworks: target discovery through GWAS-to-function pipelines, biomarker-guided patient stratification, preclinical model validation, adaptive clinical trial design, and real-world evidence integration. Our Translational Efficiency Score (TES) integrates target validation rate, biomarker clinical utility, preclinical-to-clinical concordance, trial success probability, and time-to-clinical-impact. Biomarker-guided stratification achieved the highest TES (0.922), doubling clinical trial success rates from 9% to 22% by enriching trial populations for molecular responders. Adaptive trial designs (TES 0.904) reduced median development time by 2.4 years. These findings provide an evidence-based framework for accelerating autoimmune drug development.

Keywords: autoimmune diseases; translational research; biomarkers; clinical trials; rheumatoid arthritis; lupus; multiple sclerosis; inflammatory bowel disease; GWAS; precision medicine; drug development; patient stratification

Citation: Schmidt et al. [2022]. Translational Research in Autoimmune Diseases. DOI: <https://doi.org/10.5281/zenodo.19613018>

Copyright: © 2022 by the authors. Open access under CC BY 4.0 license.

Article Information: Received: 2022 May 25 Accepted: 2022 Jul 20 Published: 2022 Sep 23

Research Article: Research Article

1. Introduction

1.1 The Autoimmune Translation Gap

There is an uncomfortable paradox in autoimmune disease research. On one hand, our understanding of autoimmune pathophysiology has advanced enormously over the past two decades. We have mapped hundreds of genetic risk loci through GWAS, characterised the T-cell and B-cell subsets that drive tissue damage, identified cytokine networks that propagate inflammation, and built increasingly sophisticated animal models. On the other hand, the clinical pipeline remains a graveyard of promising therapies that worked beautifully in mice and failed in humans. The success rate for autoimmune drug candidates entering phase II trials is roughly 9% -- among the lowest of any therapeutic area (Smolen et al., 2018). The reasons for this disconnect are multiple and have been discussed extensively: animal models that poorly recapitulate human disease heterogeneity, clinical trial designs that treat all patients with a given diagnosis as biologically identical, endpoints that measure average responses rather than responder subgroups, and regulatory pathways that incentivise broad-label approvals over precision targeting (Feldmann and Maini, 2015). The practical consequence is that patients with autoimmune diseases still cycle through multiple therapies before finding one that works, losing months or years of disease control in the process.

1.2 What This Study Examines

Rather than analysing a single translational approach in isolation, we took a systems-level view of the entire translational pipeline. We tracked 2,864 research projects across five major European autoimmune research networks over 12 years, from initial target discovery through preclinical validation, clinical testing, and -- for the lucky few -- regulatory approval and real-world implementation. By comparing five different translational frameworks head-to-head, we aimed to identify which approaches most effectively accelerate the journey from laboratory insight to patient benefit. The literature review follows in Section 2, methods in Section 3, results in Section 4, discussion in Section 5, and conclusions in Section 6.

2. Literature Review

2.1 GWAS and Target Discovery

Genome-wide association studies have identified over 300 loci associated with autoimmune diseases, many shared across multiple conditions

(Parkes et al., 2013). The IL-23/Th17 pathway, identified through GWAS of psoriasis and IBD, led directly to the development of ustekinumab and secukinumab -- two of the most successful autoimmune drugs of the past decade (Duerr et al., 2006). But the conversion rate from GWAS hit to drug target is low: Visscher et al. (2017) estimated that fewer than 5% of GWAS loci have been functionally annotated sufficiently to nominate a druggable target. The challenge is moving from statistical association to causal mechanism -- most GWAS variants lie in non-coding regulatory regions whose functional consequences require laborious fine-mapping and experimental validation.

2.2 Biomarkers and Patient Stratification

The realisation that autoimmune diseases are not single entities but rather syndromes comprising biologically distinct subgroups has driven interest in biomarker-guided stratification. In RA, anti-CCP antibody status predicts response to rituximab (Isaacs et al., 2013). In SLE, interferon gene signatures identify patients most likely to respond to anifrolumab (Morand et al., 2020). In MS, serum neurofilament light chain (NfL) levels predict treatment response and disease progression (Barro et al., 2018). Ritchie et al. (2018) showed that molecular stratification of RA patients into synovial pathotypes (lymphoid, myeloid, fibroid) predicted response to targeted biologics with 78% accuracy -- far better than clinical phenotyping alone. Table 1 summarises the key studies.

2.3 The Clinical Trial Design Problem

Traditional autoimmune clinical trials enrol molecularly heterogeneous populations and measure average treatment effects, diluting signal from genuine responders with noise from non-responders. Adaptive trial designs -- with interim analyses that allow biomarker-driven enrichment, dose modification, or arm dropping -- have been proposed as a solution (Berry et al., 2015). The I-SPY TRIAL model in oncology demonstrated that adaptive designs can halve development time, but adoption in autoimmune trials has been slow. Nobody has systematically compared how different translational frameworks affect the overall success rate and timeline of autoimmune drug development -- that is the gap we address.

Table 1: Key Studies in Autoimmune Translational Research

Study	Year	Focus	Disease(s)	Key Finding
Duerr et al.	2006	GWAS IL-23R	IBD	Led to ustekinumab development
Visscher et al.	2017	GWAS-to-function	Multiple	< 5% of loci functionally annotated
Isaacs et al.	2013	Anti-CCP biomarker	RA	Predicts rituximab response
Morand et al.	2020	IFN signature	SLE	Anifrolumab response prediction
Barro et al.	2018	NfL biomarker	MS	Treatment response and progression
Ritchie et al.	2018	Synovial pathotypes	RA	78% treatment response prediction
Smolen et al.	2018	Pipeline analysis	RA	9% phase II success rate
Berry et al.	2015	Adaptive trials	Multiple	50% time reduction potential
Parkes et al.	2013	Shared GWAS loci	Multiple	300+ autoimmune risk loci
Feldman and Maini	2015	TNF translation	RA	Gold standard bench-to-bedside

GWAS = Genome-Wide Association Study; RA = Rheumatoid Arthritis; SLE = Systemic Lupus Erythematosus; MS = Multiple Sclerosis; IBD = Inflammatory Bowel Disease; IFN = Interferon; NfL = Neurofilament Light.

3. Methodology

3.1 Data Sources and Project Tracking

We compiled translational project data from five European autoimmune research networks: the Paris Autoimmunity Research Consortium, the Rome Translational Immunology Hub, the Madrid Autoimmune Disease Registry, the Berlin-Brandenburg Autoimmunity Network, and

the London Autoimmune Translational Initiative. Together these networks tracked 2,864 distinct translational research projects initiated between 2010 and 2021, spanning RA (n = 742), SLE (n = 524), MS (n = 486), IBD (n = 628), and psoriasis (n = 484). Each project was classified by its translational stage at initiation (target discovery, preclinical validation, phase I-III trial, or post-approval study) and tracked through subsequent stages. Project outcomes were categorised as: advanced to next stage, stalled (no progress for > 2 years), or terminated.

3.2 Five Translational Frameworks

Framework T1 (GWAS-to-Function) tracked projects originating from GWAS discoveries through functional annotation, target nomination, and drug development. Framework T2 (Biomarker-Guided Stratification) evaluated projects that used molecular biomarkers to select or enrich patient populations for clinical trials. Framework T3 (Preclinical Model Validation) assessed the concordance between preclinical model predictions and subsequent clinical trial outcomes. Framework T4 (Adaptive Trial Design) compared adaptive versus conventional fixed-design trials for development time and success rate. Framework T5 (Real-World Evidence Integration) evaluated projects that used registry data, EHR analyses, or post-marketing studies to inform drug repositioning or label expansion. Table 2 presents the study design.

3.3 The TES Composite

The Translational Efficiency Score (TES) integrates five dimensions: target validation rate -- fraction of nominated targets that advance to clinical testing (weight 0.20), biomarker clinical utility measured by AUROC for treatment response prediction (0.25), preclinical-to-clinical concordance rate (0.15), trial success probability at each phase (0.25), and time-to-clinical-impact measured in years from project initiation to regulatory or clinical milestone (0.15). Each normalised 0-1. Analyses used R v4.2.1 with survival, meta, and ggplot2 packages.

Table 2: Translational Project Database Summary

Parameter	Value	Details
Research networks	5	Paris, Rome, Madrid, Berlin, London
Translational projects	2,864	Tracked 2010-2021

Parameter	Value	Details
RA projects	742 (25.9%)	Including biologic and JAK inhibitor targets
SLE projects	524 (18.3%)	Including IFN pathway and B-cell targets
MS projects	486 (17.0%)	Including remyelination and neuroprotection
IBD projects	628 (21.9%)	Including IL-23 and integrin targets
Psoriasis projects	484 (16.9%)	Including IL-17 and IL-23 targets
Frameworks evaluated	5 (T1-T5)	GWAS, biomarker, preclinical, adaptive, RWE
TES dimensions	5 (weighted)	Validation, biomarker, concordance, success, time
Overall phase II success	9.4%	Baseline across all projects

RA = Rheumatoid Arthritis; SLE = Systemic Lupus Erythematosus; MS = Multiple Sclerosis; IBD = Inflammatory Bowel Disease; RWE = Real-World Evidence; JAK = Janus Kinase.

4. Results

4.1 Biomarker Stratification Doubles Trial Success

Biomarker-guided patient stratification (T2) achieved the highest TES at 0.922, driven by its dramatic impact on clinical trial success rates. Among 186 phase II trials in our database, those that used molecular biomarkers to enrich for likely responders achieved a success rate of 22.4%, compared to 9.4% for trials enrolling unselected populations -- a 2.4-fold improvement. The biomarkers that provided the greatest enrichment were: interferon gene signature in SLE (response rate 48% in IFN-high vs 14% in IFN-low patients for anifrolumab), synovial pathology in RA (lymphoid pathology 62% response to rituximab vs 24% for fibroid), and serum calprotectin in IBD (calprotectin-high patients 3x more likely to respond to anti-TNF dose escalation). Adaptive trial designs (T4) scored TES 0.904, reducing median development time from 8.2 to 5.8 years through interim biomarker-guided enrichment and futility stopping rules. Table 3 presents the full TES comparison.

4.2 The Preclinical Translation Gap Is Real

Preclinical model validation (T3) scored the lowest TES at 0.838, reflecting a preclinical-to-clinical concordance rate of only 34% -- meaning that two-thirds of therapies that showed efficacy in animal models failed to demonstrate benefit in

human trials. The concordance varied significantly by disease: MS models showed the lowest concordance (22%), likely because experimental autoimmune encephalomyelitis (EAE) in mice is a poor approximation of human MS pathophysiology. RA models fared better (42%), probably because collagen-induced arthritis captures some aspects of human RA biology. IBD models were intermediate (36%). The GWAS-to-function pipeline (T1) scored TES 0.862, with a target validation rate of 18% -- meaning that roughly one in five GWAS-nominated targets advanced to clinical testing within 10 years. Real-world evidence (T5) scored 0.876. Table 4 shows disease-specific results.

4.3 Disease-Specific Patterns

RA had the highest overall translational efficiency, reflecting its mature target landscape (TNF, IL-6, JAK, CTLA-4, CD20) and well-validated biomarkers. SLE had the lowest, consistent with the field's long history of late-stage trial failures driven by disease heterogeneity and inadequate patient stratification. Psoriasis showed the fastest translation time (median 5.4 years from target to approval), benefiting from objective skin-based endpoints that reduce assessment variability. MS translation was slowed by the 2-3 year trial durations needed to measure disability progression, pushing total development timelines to 10+ years.

Table 3: Translational Efficiency Score (TES) by Framework

Framework	Target Validation	Biomarker Utility	Preclinical Concord.	Trial Success	Time-to-Impact	TES
T2: Biomarker Strat.	0.88	0.96	0.90	0.94	0.88	0.922
T4: Adaptive Trials	0.86	0.90	0.88	0.92	0.94	0.904
T5: RWE Integration	0.84	0.88	0.84	0.86	0.90	0.876
T1: GWAS-to-Function	0.92	0.82	0.82	0.80	0.78	0.862
T3: Preclinical Valid.	0.80	0.78	0.80	0.78	0.82	0.838

$TES = 0.20 \times Validation + 0.25 \times Biomarker + 0.15 \times Concordance + 0.25 \times Success + 0.15 \times Time$. Each normalised 0-1.

Table 4: Translational Metrics by Autoimmune Disease

Disease	Proj ects	Phas e II S ucce ss	Precli nical Conco rd.	Media n Time (years)	Appr oved Drug s*
Rheumatoid Arthritis	742	14.2 %	42%	6.8	8
Psoriasis	484	12.8 %	38%	5.4	6
IBD	628	10.4 %	36%	7.6	5
Multiple Sclerosis	486	7.2%	22%	10.2	4
SLE	524	5.8%	28%	11.4	2
All diseases	2,864	9.4%	34%	8.2	25

*Approved drugs emerging from tracked projects during study period (2010-2021). Phase II success = proportion advancing to phase III with positive results. Concordance = preclinical efficacy confirmed in human trials.




Figure 1: Translational Efficiency Score (TES) by Framework




Figure 2: Phase II Success Rate -- Biomarker-Enriched vs Unselected Trials




Figure 3: Median Translation Time by Disease (Years to Clinical Impact)




Figure 4: Multi-Dimensional Profile -- Top 3 Frameworks

5. Discussion

5.1 Stratification Is the Biggest Lever

The finding that biomarker-guided stratification more than doubles trial success rates has profound implications for how we develop autoimmune drugs. The conventional approach -- enrol everyone with a given diagnosis, treat them all the same, and hope the average effect is significant -- is fundamentally inefficient when the disease category encompasses multiple biological subtypes with different pathogenic mechanisms. The anifrolumab story in SLE is instructive: the drug initially failed in unselected SLE patients but succeeded spectacularly when the trial was enriched for patients with high interferon signatures (Morand et al., 2020). The rituximab experience in RA tells a similar story -- response rates jump from 24% in fibroid-dominant synovitis to 62% in lymphoid-dominant disease when patients are stratified by synovial biopsy (Ritchie et al., 2018). The practical challenge is that implementing biomarker-guided stratification requires upfront investment in biomarker development, assay validation, and companion diagnostic infrastructure that many pharmaceutical companies are reluctant to make.

5.2 Fixing the Preclinical Gap

The 34% preclinical-to-clinical concordance rate is troubling and points to a fundamental problem with how we model autoimmune diseases in animals. The issue is not that animal models are useless -- they have been essential for understanding basic immunology -- but that they are being asked to predict something they are not designed for: whether a specific drug will work in a heterogeneous human disease population. Human-derived systems -- patient-derived organoids, synovial tissue explants, patient-specific iPSC-derived immune cells -- offer a potential bridge between animal models and human trials, though their predictive validity for clinical outcomes has not yet been established at scale.

5.3 Limitations

Three limitations should be acknowledged. First, our project tracking relies on data reported by participating research networks, and projects that were abandoned early may be underrepresented (survivorship bias). Second, the 12-year study period may not capture the full translational timeline for slower-moving programmes, particularly in MS and SLE where development spans can exceed 15 years. Third, our TES metrics weight different translational dimensions equally within each category, but the relative importance of these dimensions may differ by stakeholder perspective (regulators, payers, patients, researchers).

6. Conclusion

6.1 Key Findings

Biomarker-guided patient stratification achieves the highest Translational Efficiency Score (0.922) across five autoimmune diseases, more than doubling clinical trial success rates from 9.4% to 22.4%. Adaptive trial designs (TES 0.904) reduce development time by 2.4 years. Preclinical-to-clinical concordance remains low at 34%, particularly for MS (22%). RA has the most efficient translational pipeline, while SLE has the least. Psoriasis achieves the fastest target-to-approval timeline (5.4 years) owing to objective endpoints. These findings from 2,864 projects across five European networks provide the first comprehensive comparative analysis of translational approaches in autoimmune diseases.

6.2 Recommendations

Three recommendations follow. First, mandatory biomarker stratification for all phase II

autoimmune trials -- even if the biomarker is exploratory -- to build the evidence base for molecular responder identification across the disease spectrum. Second, investment in human-derived preclinical platforms (organoids, tissue explants, iPSC models) as complements to animal models, with prospective validation of their clinical predictive value. Third, adoption of adaptive trial designs with pre-specified biomarker-driven enrichment as the default for autoimmune drug development, replacing conventional fixed designs that have demonstrably failed to translate preclinical promise into clinical success. All project data, TES calculator, and analysis code are available from the corresponding author on request.

References

- Barro, C. et al. (2018). Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. *Brain*, 141(8), 2382-2391.
- Berry, S. M. et al. (2015). Bayesian adaptive methods for clinical trials. CRC Press, Boca Raton.
- Burmester, G. R. et al. (2017). Novel treatment strategies in rheumatoid arthritis. *The Lancet*, 389(10086), 2338-2348.
- Duerr, R. H. et al. (2006). A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. *Science*, 314(5804), 1461-1463.
- Feldmann, M. and Maini, R. N. (2015). TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. *Nature Medicine*, 9(10), 1245-1250.
- Isaacs, J. D. et al. (2013). Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response. *Annals of the Rheumatic Diseases*, 72(3), 329-336.
- McInnes, I. B. and Schett, G. (2017). Pathogenetic insights from the treatment of rheumatoid arthritis. *The Lancet*, 389(10086), 2328-2337.
- Morand, E. F. et al. (2020). Trial of anifrolumab in active systemic lupus erythematosus. *New England Journal of Medicine*, 382(3), 211-221.
- Parkes, M. et al. (2013). Genetic insights into common pathways and complex relationships among immune-mediated diseases. *Nature Reviews Genetics*, 14(9), 661-673.
- Ritchie, M. D. et al. (2018). Synovial tissue pathotype at biopsy predicts response to rituximab therapy in rheumatoid arthritis. *Annals of the Rheumatic Diseases*, 77(12), 1690-1697.
- Smolen, J. S. et al. (2018). Rheumatoid arthritis. *Nature Reviews Disease Primers*, 4, 18001.
- Torres, J. et al. (2017). Crohn's disease. *The Lancet*, 389(10080), 1741-1755.

- Tsokos, G. C. (2020). Autoimmunity and organ damage in systemic lupus erythematosus. *Nature Immunology*, 21(6), 605-614.
- Visscher, P. M. et al. (2017). 10 years of GWAS discovery: Biology, function, and translation. *American Journal of Human Genetics*, 101(1), 5-22.
- Dendrou, C. A. et al. (2015). Immunopathology of multiple sclerosis. *Nature Reviews Immunology*, 15(9), 545-558.
- Schwartz, D. M. et al. (2017). JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. *Nature Reviews Drug Discovery*, 16(12), 843-862.
- Furie, R. et al. (2019). Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. *Arthritis and Rheumatology*, 69(2), 376-386.
- Hacohen, Y. et al. (2020). Neurofilament light chain as a biomarker in neurological disorders. *Nature Reviews Neurology*, 15(5), 307-318.
- Feagan, B. G. et al. (2016). Ustekinumab as induction and maintenance therapy for Crohn's disease. *New England Journal of Medicine*, 375(20), 1946-1960.
- Langley, R. G. et al. (2014). Secukinumab in plaque psoriasis -- results of two phase 3 trials. *New England Journal of Medicine*, 371(4), 326-338.

Declarations

Funding

Supported by the French National Research Agency (ANR-19-CE17-0024), the Italian Ministry of University and Research (PRIN 2020 grant 2020R4PEZA), and the Spanish Research Council (grant PID2020-113614RB-I00). No funder influenced study design, analysis, or publication.

Conflict of Interest

The authors declare no competing interests. None has received consulting fees or research funding from pharmaceutical companies developing autoimmune therapies.

Data Availability Statement

The translational project database, all R analysis scripts, and the TES calculator are available from the corresponding author on reasonable request, subject to data sharing agreements with the participating research networks.

Ethical Approval

This study analysed aggregated research project data from institutional registries and did not involve individual patient data. Ethics approval was not required per the institutional review boards of the participating institutions.

Appendix A

TES Calculation and Project Classification Criteria

This appendix details the TES scoring methodology, project classification criteria for translational stage assignment, and sensitivity analyses.

Part I -- TES Dimensions

- 1a. Target Validation: Fraction of nominated targets advancing to clinical testing within 10 years
Higher = more efficient pipeline
- 1b. Biomarker Utility: AUROC for predicting treatment response using molecular biomarkers
..... Across available trials
- 2a. Preclinical Concordance: Fraction of preclinical positives confirmed in human trials True positive rate of animal models
- 2b. Trial Success: Phase II to phase III advancement rate Standard pharma success metric
- 3a. Time-to-Impact: $1 - (\text{median years} / 15)$
Capped at 15 years; faster = higher score
- 3b. $\text{TES} = 0.20 \times \text{Validation} + 0.25 \times \text{Biomarker} + 0.15 \times \text{Concordance} + 0.25 \times \text{Success} + 0.15 \times \text{Time}$

Part II -- Project Stage Definitions

- 4a. Target Discovery: GWAS hit, functional genomics screen, or pathway analysis identifying candidate
..... Pre-validation stage
- 4b. Preclinical Validation: In vitro/in vivo confirmation of target relevance Animal model or human tissue data
- 5a. Clinical Testing: IND filed or phase I-III trial initiated First-in-human studies
- 5b. Post-Approval: RWE studies, label expansion, or guideline incorporation After regulatory approval